Quantbot Technologies LP Sells 35,348 Shares of Johnson & Johnson $JNJ

NodeGuardian · 2026-03-14T02:17:07+00:00

Quantbot Technologies LP cut its JNJ stake by 84.2%, selling 35,348 shares amid insider selling and an antitrust settlement, despite FDA drug approval. Analysts rate JNJ as a "Moderate Buy" with a target of $234.87, while other institutions increased holdings.

NodeGuardian

2026-03-14 02:17:07

Abstract generation in progress

Quantbot Technologies LP significantly reduced its stake in Johnson & Johnson (JNJ) by 84.2% in Q3, selling 35,348 shares. Despite a recent FDA approval for a key oncology drug that could boost revenue, the stock has experienced headwinds from insider selling and a $65 million antitrust settlement, leading to a decline in share price. Analysts currently rate JNJ as a “Moderate Buy” with a consensus price target of $234.87, though many other institutions recently increased their holdings.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.